Melanoma & Skin Cancer

Experts from across the oncology field highlight their biggest takeaways and the hottest topics from the 2024 AACR Annual Meeting.

Nivolumab plus talazoparib did not produce RECIST-based tumor responses in heavily pretreated patients with unresectable or metastatic melanoma.

Ipilimumab plus nivolumab increased response rates vs anti–PD-1 monotherapy, but also increased grade 3 or 4 immune-related adverse effects, in melanoma.

Michael R. Migden, MD, discusses efficacy data for RP1 in advanced non-melanoma skin cancer after prior solid organ transplant.

China’s NMPA has approved tunlametinib for the treatment of patients with NRAS-mutated advanced melanoma after prior anti–PD-1/PD-L1 therapy.

The addition of UV1 to nivolumab/ipilimumab failed to improve PFS in the frontline treatment of unresectable or metastatic melanoma.

Daniel Olson, MD, discusses the FDA approval of lifileucel for patients with advanced melanoma whose disease has been previously treated.

Neil D. Gross, MD, FACS, discusses key safety data from a phase 2 study of neoadjuvant cemiplimab in cutaneous squamous cell carcinoma.

In case you missed it, below is a recap of all drugs that have been approved by the FDA in February 2024.

Daniel Olson, MD, discusses the significance of the FDA approval of lifileucel for patients with advanced melanoma.

Nikhil I. Khushalani, MD, of Moffitt Cancer Center, discusses current therapeutic options for patients with locally advanced cutaneous squamous cell carcinoma.

Nikhil I. Khushalani, MD, of Moffitt Cancer Center, discusses the diagnosis and prognosis of patients with locally advanced cutaneous squamous cell carcinoma.

Neil D. Gross, MD, FACS, discusses a phase 2 study evaluating neoadjuvant cemiplimab in cutaneous squamous cell carcinoma.

Harriet Kluger, MD, discusses the FDA approval of the tumor infiltrating lymphocyte therapy lifileucel for patients with advanced melanoma.

The FDA has approved lifileucel suspension (Amtagvi) for adult patients with unresectable or metastatic melanoma following prior treatment with a PD-1 inhibitor, and if BRAF V600 mutation positive, a BRAF inhibitor, with or without a MEK inhibitor.

The FDA has granted clearance for the first real-time, non-invasive skin cancer evaluation system .

The BLA seeking the approval of denileukin diftitox in patients with relapsed/refractory cutaneous T-cell lymphoma was resubmitted to the FDA.

In the treatment of unresectable or metastatic Merkel cell carcinoma, immune checkpoint inhibitors have activity and tolerability.

Paul D. Nathan, MBBS, PhD, FRCP, discusses the clinical significance of updated data on tebentafusp in metastatic uveal melanoma.

Adjuvant nivolumab significantly improved relapse-free survival vs ipilimumab in resected stage III/IV melanoma, according to 7-year minimum follow-up.

Preferentially expressed antigen in melanoma has emerged as a target for treatment development in multiple solid tumors.

Jeffrey S. Weber, MD, PhD, discusses the background for the KEYNOTE-942 trial, which was conducted in resected high-risk melanoma.

Oncologists reviewed data from clinical trials in the field of melanoma that could add clarity to treatment standards and lead to improved patient care.

The initiation of immunotherapy at the end of life among patients with advanced cancers is increasing over time.

Jeffrey S. Weber, MD, PhD, expands on the potential utility of longitudinal ctDNA dynamics as a kinetic marker for clinical outcomes in melanoma.